Grandfield & Dodd LLC Purchases 1,182 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Grandfield & Dodd LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 7.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,146 shares of the pharmaceutical company's stock after acquiring an additional 1,182 shares during the period. Grandfield & Dodd LLC's holdings in Vertex Pharmaceuticals were worth $8,798,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of VRTX. Mascagni Wealth Management Inc. acquired a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $31,000. SJS Investment Consulting Inc. increased its stake in Vertex Pharmaceuticals by 46.2% during the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock valued at $46,000 after buying an additional 30 shares during the period. Mpwm Advisory Solutions LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $40,000. Minot DeBlois Advisors LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $44,000. Finally, City State Bank increased its stake in Vertex Pharmaceuticals by 746.2% during the 1st quarter. City State Bank now owns 110 shares of the pharmaceutical company's stock valued at $53,000 after buying an additional 97 shares during the period. Institutional investors and hedge funds own 90.96% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on VRTX shares. Wolfe Research lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, May 7th. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Bank of America raised their price objective on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research report on Monday, March 31st. Finally, Leerink Partners restated a "market perform" rating and set a $503.00 price objective (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $511.71.

Vertex Pharmaceuticals Stock Down 0.1%

VRTX traded down $0.64 during midday trading on Friday, hitting $462.63. 384,820 shares of the company's stock traded hands, compared to its average volume of 1,418,569. The company has a market cap of $118.80 billion, a PE ratio of -118.19 and a beta of 0.41. The stock's fifty day simple moving average is $448.80 and its 200-day simple moving average is $462.07. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. Vertex Pharmaceuticals's revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $4.76 EPS. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.